News

Technique for finding small molecules

Software facilitates high-content analysis of membrane vesicles
Aran Sullivan
By Aran Sullivan
April 16, 2022

Lipid rafts, a component of the plasma membranes that surround all cells in the human body, are essential in regulating the membranes’ structure, among other functions. But they are hard to study because traditional biochemical methods tend to destroy them. 

Chuck Sanders of Vanderbilt University and his lab collaborated with corresponding author Anne Kenworthy at the University of Virginia School of Medicine to develop new techniques for discovering the small molecules that regulate lipid rafts. Their article was published in ACS Central Science in February. 

“Raft-modulatory small molecules are likely an important part of fundamental biological processes,” Sanders said. “Lipid rafts are like a clique at a party — always together. This work describes a way of discovering the small molecules that either ‘dissolve’ these molecular cliques or that enhance their formation.” 

Lipid rafts are composed of lipids and proteins that stick together as they move within the plasma membrane, like small rafts in the ocean. They assist in cellular transport, signal transduction and immune system functions. For example, the enzymes responsible for production of the amyloid-beta polypeptide closely associated with Alzheimer’s disease are thought to reside in lipid rafts.  

A microscopy-based method to identify small molecules that function as raft modulators in cell-derived plasma membranes.

So learning more about the molecules that regulate lipid raft function may turn out to be disease therapeutic. In addition to Alzheimer’s, alterations in lipid rafts have been associated with cancer cells that are resistant to chemotherapy. These molecules will also be important research tools that will better enable investigators to study the roles of rafts in healthy and diseased biological processes. 

“In the short term, the robust methods described in this work should lead to the discovery of small molecule tools that can be used either to enhance or to suppress lipid raft formation in research,” Sanders said. “In the long term, we hope some of the molecules discovered will have utility in research, biotechnology and medicine.”  

Kenworthy

Kenworthy said that the "biggest trick" to setting up the screen "was to figure out how to detect and quantify the effects of small molecules on raft stability on a large scale."

She continued: "We quickly settled on using giant plasma membrane vesicles — GPMVs — as a model to visualize raft formation, since this is easy to do using fluorescence microscopy.  Coming up with a strategy to analyze the many images of GPMVs generated during the screen in an unbiased way was much harder.  We ultimately developed a high content image analysis pipeline that allowed us to analyze rafts in literally thousands of vesicles in an automated fashion. "

The screening technique is up for a patent that will be shared by Vanderbilt and the University of Virginia. The Sanders lab will expand and refine the screening approach described in this paper.  

“We are seeking to further this approach to discover small molecules that specifically assist with driving membrane proteins in and out of the lipid rafts,” Sanders said.  This research was initiated with support from the inaugural Stanley Cohen Innovation Fund grant and the National Institutes of Health. The Stanley Cohen Innovation Fund from Vanderbilt supports innovative and high-risk research at its early stages. It was made in honor of Stanley Cohen, a Nobel laureate and previous distinguished professor of biochemistry, emeritus at Vanderbilt. 

The Vanderbilt High Throughput Screening Facility headed by Joshua Bauer played a key role in this work. 

This article appeared originally in Research News @ Vanderbilt and was republished and adapated with permission.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Aran Sullivan
Aran Sullivan

Aran Sullivan is a writer for Vanderbilt University. 

Related articles

From the journals: June/July 2019
Courtney Chandler, Isha Dey & Jonathan Griffin
From the journals: March 2019
John Arnst, Courtney Chandler, Isha Dey & Catherine Goodman
From the journals: May 2018
Sasha Mushegian & Laurel Oldach
From the journals: March 2018
Sasha Mushegian, Laurel Oldach & Saddiq Zahari
From the journals: MCP
Renae Crossing

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Seeking the sweet spot to beat a pig parasite
Journal News

Seeking the sweet spot to beat a pig parasite

July 16, 2024

Researchers extracted, separated and tested glycans from the porcine whipworm in an effort to determine the best way to develop treatments and vaccines.

Radioactive drugs strike cancer with precision
News

Radioactive drugs strike cancer with precision

July 14, 2024

The tumor-seeking radiopharmaceuticals are charting a new course in oncology, with promise for targeted treatments with fewer side effects.

Animals have used bioluminescence to communicate for millions of years
News

Animals have used bioluminescence to communicate for millions of years

July 13, 2024

Despite its widespread occurrence, scientists don’t yet know when or where this phenomenon first emerged, or its original function.

Getting to the genetic basis of cardiovascular disease
Journal News

Getting to the genetic basis of cardiovascular disease

July 11, 2024

Edwin G. Peña Martínez received a JBC Tabor award for associating the condition with mutations in noncoding sequences.

Microparticles safeguard vitamins and information
News

Microparticles safeguard vitamins and information

July 9, 2024

Scientists aim to use nanotechnology to combat malnutrition and improve medical recordkeeping in impoverished parts of the world.

Why AlphaFold 3 needs to be open source
Essay

Why AlphaFold 3 needs to be open source

July 7, 2024

The powerful AI-driven software from DeepMind was released without making its code openly available to scientists.